Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020

Operational Highlights for Q4 2020 Operational Highlights for Q4 2020 Operational Highlights for the Full Year 2020 The balance of funds will support organic growth initiatives, and corporate purposes. Post-period Highlights Financial Highlights for the 12-month Period ended31 December 2020 *Convenience conversion to US$ at the following rates: 2020:1US$= 106.774 JPY ; 2019:1US$= 109.035 JPY**Non-IFRS measure About Sosei Heptares We are an...

Operational Highlights for Q4 2020

Operational Highlights for the Full Year 2020

The balance of funds will support organic growth initiatives, and corporate purposes.

Post-period Highlights

Financial Highlights for the 12-month Period ended 31 December 2020

*Convenience conversion to US$ at the following rates: 2020: 1US$ =106.774 JPY; 2019: 1US$ =109.035 JPY
**Non-IFRS measure

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world's leading pharmaceutical companies, including AbbVie, AstraZeneca, Biohaven, Genentech (Roche), GSK, Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.

"Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit https://soseiheptares.com/ 
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco

Enquiries:

Sosei Heptares – Media and Investor Relation
Hironoshin Nomura
SVP Investor Relations and Corporate Strategy
+81 (0)3 6679 2178
[email protected]

Shinichiro Nishishita
VP Investor Relations
Head of Regulatory Disclosures
+81 (0)3 5210 3399 
[email protected]

Citigate Dewe Rogerson (for Sosei Heptares)
Yas Fukuda – Japanese Media
+81 (0)3 4360 9234
[email protected]

Mark Swallow
David Dible – International Media
+44 (0)20 7638 9571 
[email protected]

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.